Loading organizations...
I am unable to complete the company profile for 'SpareM'. My web searches did not yield sufficient, verifiable information about a company named 'SpareM' that aligns with the context of a technology company for a VC audience. Attempts to access relevant company profile pages, such as Crunchbase, were blocked. The available search results primarily pointed to either domain registration services or unrelated topics, making it impossible to gather the necessary details regarding core product, founders, origin story, customers, or vision. Without concrete data, I cannot adhere to the strict requirements for the profile's content and structure.
SpareM has raised $290K across 2 funding rounds.
SpareM has raised $290K in total across 2 funding rounds.
No technology company named SpareM appears in available sources. Search results instead highlight companies in the sperm separation and sperm analysis sectors, such as Merck, Thermo Fisher, Hamilton Thorne, BioMedomics, and QART Medical, which develop devices for fertility treatments like IVF.[1][2][3][4][5] These firms address reproductive health challenges by improving sperm selection precision, automation, and efficiency in assisted reproductive technologies (ART), serving fertility clinics, hospitals, and research labs amid rising global demand for IVF solutions.[1][2]
The sperm separation devices market is projected to reach $4.2 billion by 2030, driven by advancements in centrifugation, AI, and microfluidics, while sperm analytical devices are expected to grow by $84.26 million from 2023-2028 at a 6.42% CAGR.[1][5] QART Medical, a notable startup, offers innovative 3D imaging for high-quality sperm selection without chemical staining, doubling IVF success rates in trials.[2]
Search results lack details on a company called SpareM. Instead, they reference established players like Sperm Analysis Technologies (SpermTech), with over 25 years in seminal analysis equipment development and commercialization.[3] QART Medical emerged from Tel Aviv University's Biomedical Engineering lab under Prof. Natan T. Shaked, supported by the university's investment fund Ramot and external investors; its technology, published in journals like PNAS, gained early traction through clinical trials at Israeli hospitals (e.g., Barzilai, Meir) and international sites like UCSF and University of Tokyo.[2]
Other firms like Merck and Thermo Fisher evolved through R&D investments in reproductive health, expanding from general biotech into ART-specific sperm tech.[1] Hamilton Thorne and BioMedomics built on precision instruments and cost-effective microfluidics, targeting global growth in North America, Europe, and Asia-Pacific.[1]
These companies ride the ART and fertility tech boom, fueled by rising infertility rates, delayed parenthood, and demand in emerging markets like Asia-Pacific.[1][2] Timing aligns with IVF market growth—sperm separation devices doubling revenue to $816.5 million by 2028—boosted by regulatory support and clinic adoption.[4] Market forces include automation needs to improve efficiency/precision and affordable tech for developing regions.[1][5]
They influence the ecosystem by enabling higher IVF success (e.g., QART's doubling effect), supporting university-tech transfers like Ramot's model, and expanding access via partnerships with global clinics.[2] This shifts fertility from manual to tech-driven, contributing to economic impact through startups and R&D.[2]
Without SpareM data, focus shifts to sector leaders: expect accelerated growth via AI/microfluidics integration and emerging market penetration, with markets expanding significantly by 2030.[1][5] Trends like non-invasive imaging (e.g., QART) and automation will shape trajectories, potentially evolving influence toward personalized fertility solutions and broader biotech adoption.[2] Investors eye high returns in this high-impact niche, tying back to unmet reproductive health needs unmet by traditional methods.
SpareM has raised $290K in total across 2 funding rounds.
SpareM's investors include FasterCapital.
SpareM has raised $290K across 2 funding rounds. Most recently, it raised $180K Seed in September 2016.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2016 | $180K Seed | FasterCapital | |
| Jan 1, 2014 | $110K Seed | FasterCapital |